Core Viewpoint - Rocket Pharmaceuticals, Inc. is facing a class action securities lawsuit due to alleged securities fraud related to the safety and clinical trial protocol of its RP-A501 treatment, which resulted in significant stock price decline after the FDA placed a clinical hold on the study [1][2]. Group 1: Lawsuit Details - The lawsuit aims to recover losses for investors affected by alleged securities fraud between September 17, 2024, and May 26, 2025 [1]. - Defendants allegedly made positive statements while concealing material adverse facts about RP-A501's safety, including the risk of Serious Adverse Events (SAEs) [2]. - Following the announcement of a clinical hold by the FDA due to a SAE, Rocket's stock price plummeted from $6.27 to $2.33, a decline of approximately 37% in one trading day [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the relevant timeframe have until August 11, 2025, to request appointment as lead plaintiff, although participation does not require this role [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as a leading securities litigation firm in the U.S. [4].

Core Viewpoint - A class action lawsuit has been filed against Rocket Pharmaceuticals, alleging violations of the Securities Exchange Act of 1934 related to misleading information about its clinical trials and safety protocols [1][4][5]. Group 1: Lawsuit Details - The lawsuit, titled Ho v. Rocket Pharmaceuticals, Inc., is pending in the District of New Jersey and seeks to represent purchasers of Rocket Pharmaceuticals' securities [1]. - A subsequent case, Yankov v. Rocket Pharmaceuticals, Inc., has also been filed [1]. - The allegations include that Rocket Pharmaceuticals provided misleading information regarding its Phase 2 trial of RP-A501 for Danon disease while concealing serious risks, including participant deaths [4]. Group 2: Clinical Trial Issues - The lawsuit claims that Rocket Pharmaceuticals failed to disclose a critical amendment to the trial protocol that introduced a new immunomodulatory agent, which was linked to serious adverse events [4]. - On May 27, 2025, the U.S. FDA placed a clinical hold on the RP-A501 study after a patient died, which was not disclosed to investors at the time of the protocol amendment [5]. Group 3: Legal Process - Investors who suffered losses can seek to be appointed as lead plaintiff in the class action lawsuit, with motions due by August 11, 2025 [2][6]. - The lead plaintiff will represent the interests of all class members and can choose their legal representation [6]. Group 4: Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm in securities fraud litigation, having recovered over $2.5 billion for investors in 2024 alone [7]. - The firm has been ranked 1 in securing monetary relief for investors in securities class actions for four out of the last five years [7].

Core Viewpoint - Rocket Pharmaceuticals, Inc. is facing a class action lawsuit due to allegations of providing misleading statements regarding the safety and clinical trial protocol of its RP-A501 treatment, which resulted in significant stock price decline after the FDA placed a clinical hold on the study following a Serious Adverse Event [3][4]. Group 1: Allegations and Events - The class period for the lawsuit is from September 17, 2024, to May 26, 2025 [3]. - Allegations include that Rocket Pharmaceuticals made overwhelmingly positive statements while concealing material adverse facts about RP-A501's safety, including the risk of Serious Adverse Events (SAEs) [3]. - The company amended the trial protocol to introduce a new immunomodulatory agent without informing shareholders, which led to inflated stock prices [3]. - On May 27, 2025, Rocket announced the FDA's clinical hold on the RP-A501 Phase 2 study after a patient suffered a SAE, ultimately resulting in death [3]. - Following this announcement, Rocket's stock price plummeted from $6.27 per share on May 23, 2025, to $2.33 per share on May 27, 2025, marking a decline of approximately 37% in one trading day [3]. Group 2: Next Steps for Shareholders - Shareholders are encouraged to register for the class action lawsuit by August 11, 2025, to potentially become lead plaintiffs [4]. - Registered shareholders will receive updates through a portfolio monitoring software regarding the case's status [4]. - Participation in the case incurs no cost or obligation for shareholders [4]. Group 3: Law Firm Information - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [5]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [5].

Core Viewpoint - The Rocket Pharmaceuticals class action lawsuit alleges violations of the Securities Exchange Act of 1934, focusing on misleading information regarding the safety and clinical trial protocol of its gene therapy product RP-A501 for Danon disease [1][4]. Group 1: Lawsuit Details - The lawsuit is titled Ho v. Rocket Pharmaceuticals, Inc., No. 25-cv-10049, and is pending in the District of New Jersey, representing purchasers of Rocket Pharmaceuticals securities [1]. - A subsequent case, Yankov v. Rocket Pharmaceuticals, Inc., No. 25-cv-13532, has also been filed [1]. - The lawsuit claims that Rocket Pharmaceuticals provided material information about its Phase 2 trial while concealing adverse facts about the safety of RP-A501, including the risk of Serious Adverse Events [4]. Group 2: Clinical Trial Issues - On May 27, 2025, Rocket Pharmaceuticals announced that the FDA placed a clinical hold on the RP-A501 Phase 2 study after a patient suffered a Serious Adverse Event, leading to death [5]. - The complaint states that the company failed to disclose a substantive amendment to the trial's protocol that introduced a new immunomodulatory agent, which was critical information for investors [4][5]. Group 3: Lead Plaintiff Process - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased Rocket Pharmaceuticals securities during the Class Period to seek appointment as lead plaintiff [6]. - The lead plaintiff is typically the investor with the greatest financial interest and acts on behalf of all class members [6]. Group 4: About Robbins Geller - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder litigation, having recovered over $2.5 billion for investors in 2024 alone [7]. - The firm has been ranked 1 in securing monetary relief for investors in securities class action cases for four out of the last five years [7].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Rocket Pharmaceuticals due to misleading statements regarding the safety of its clinical trial for RP-A501, which led to significant investor losses [2][4][5]. Group 1: Legal Investigation and Claims - Faruqi & Faruqi, LLP is encouraging investors who suffered losses exceeding $50,000 in Rocket Pharmaceuticals between February 27, 2025, and May 26, 2025, to discuss their legal options [1]. - The firm has set an August 11, 2025, deadline for investors to seek the role of lead plaintiff in a federal securities class action against Rocket Pharmaceuticals [2]. - The complaint alleges that Rocket Pharmaceuticals provided positive statements while concealing material adverse facts about the safety of RP-A501 and the clinical trial protocol [4]. Group 2: Clinical Trial Issues - Rocket Pharmaceuticals faced a clinical hold from the FDA on the RP-A501 Phase 2 pivotal study after a patient suffered a Serious Adverse Event (SAE), which resulted in death [5]. - The company amended the trial protocol to introduce a new immunomodulatory agent without disclosing this critical update to investors, which is a key point of contention in the lawsuit [4][5]. Group 3: Stock Price Impact - Following the announcement of the clinical hold, Rocket's stock price plummeted from $6.27 per share on May 23, 2025, to $2.33 per share on May 27, 2025, marking a decline of approximately 37% in just one trading day [6].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Rocket Pharmaceuticals securities during the specified Class Period of the upcoming lead plaintiff deadline on August 11, 2025 [1]. Group 1: Class Action Details - Investors who purchased Rocket Pharmaceuticals securities between September 17, 2024, and May 26, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by contacting the law firm [3][6]. - The lawsuit claims that Rocket Pharmaceuticals made false and misleading statements regarding the effectiveness and safety of its product RP-A501, which led to investor damages when the truth was revealed [5]. Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4].

Core Viewpoint - Rocket Pharmaceuticals faced a significant decline in stock value after the FDA placed a clinical hold on its Phase 2 trial for RP-A501, leading to a 62% drop in share price on May 27, 2025, following the announcement of a patient's serious adverse event and subsequent death [1][9]. Group 1: Company Overview - Rocket Pharmaceuticals is a biotechnology company focused on developing gene therapies for rare diseases, specifically targeting Danon disease [4]. - The company had previously communicated strong progress in its gene therapy development, citing positive Phase 1 results as evidence of safety and efficacy [7]. Group 2: Legal Proceedings - A securities class action lawsuit has been filed against Rocket Pharmaceuticals, alleging that the company misled investors regarding the safety and progress of the RP-A501 trial [2][4]. - The lawsuit covers shareholders who purchased Rocket stock between February 27, 2025, and May 26, 2025, focusing on whether the company provided materially false and misleading statements about the trial [5]. Group 3: Allegations and Misconduct - Plaintiffs claim that Rocket Pharmaceuticals failed to disclose significant protocol changes and known risks associated with serious adverse events, including patient deaths, despite publicly expressing confidence in the trial's progress [6][8]. - The class action complaint alleges that the company amended the study protocol to introduce a new immunomodulatory agent without informing investors, which contributed to the inflated stock price prior to the FDA's announcement [8][10].

Core Viewpoint - Rocket Pharmaceuticals, Inc. is facing a class action securities lawsuit due to alleged securities fraud related to the safety and clinical trial protocol of its RP-A501 treatment, which resulted in significant stock price decline after the FDA placed a clinical hold on the study [1][2]. Group 1: Lawsuit Details - The lawsuit aims to recover losses for investors affected by alleged securities fraud between September 17, 2024, and May 26, 2025 [1]. - Defendants allegedly made positive statements while concealing material adverse facts about RP-A501's safety, including the risk of Serious Adverse Events (SAEs) [2]. - Following the announcement of a clinical hold by the FDA due to a SAE, Rocket's stock price plummeted from $6.27 to $2.33, a decline of approximately 37% in one trading day [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the relevant timeframe have until August 11, 2025, to request appointment as lead plaintiff, although participation does not require this role [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as a leading securities litigation firm in the U.S. [4].

Core Viewpoint - Berger Montague PC is investigating Rocket Pharmaceuticals for potential violations of federal securities laws related to the RP-A501 trial, which allegedly concealed safety concerns leading to significant investor losses [1][2]. Company Overview - Rocket Pharmaceuticals is based in Cranbury, New Jersey, focusing on research and clinical programs in genetic medicine [2]. - The company introduced a new immunomodulatory agent into the RP-A501 protocol without disclosing this information to shareholders, which preceded a fatal adverse event [2]. Stock Performance - Following the announcement of an FDA clinical hold, Rocket Pharmaceuticals' stock price declined nearly 37% over two trading days [2]. Legal Proceedings - A class action has been filed for individuals who purchased Rocket Pharmaceuticals securities from September 17, 2024, to May 26, 2025, with a deadline to file for lead plaintiff set for August 11, 2025 [3].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Rocket Pharmaceuticals, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline on August 11, 2025 [1]. Group 1: Class Action Details - Investors who purchased Rocket Pharmaceuticals securities between September 17, 2024, and May 26, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by August 11, 2025 [3]. - Investors are encouraged to select qualified legal counsel with a successful track record in securities class actions [4]. Group 2: Case Allegations - The lawsuit alleges that during the Class Period, defendants made false and misleading statements regarding the effectiveness and safety of RP-A501, which was overstated [5]. - Specific claims include that RP-A501 was less effective than represented, and that changes to its clinical trial protocol increased the risk of Serious Adverse Events [5].